|
Volumn 317, Issue 5, 2017, Pages 473-474
|
Privatized pharmaceutical innovation vs access to essential medicines: A global framework for equitable sharing of benefits
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EPINEPHRINE;
LEDIPASVIR;
NEW DRUG;
DRUG;
ATTITUDE TO HEALTH;
CONCEPTUAL FRAMEWORK;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG INDUSTRY;
DRUG MANUFACTURE;
ESSENTIAL MEDICINE;
FINANCIAL MANAGEMENT;
HEALTH CARE ACCESS;
HEALTH CARE POLICY;
INVESTMENT;
MEDICAL RESEARCH;
MEDICINE;
NOTE;
PATENT;
PRODUCT DEVELOPMENT;
PUBLIC-PRIVATE PARTNERSHIP;
DEVELOPED COUNTRY;
DEVELOPING COUNTRY;
ECONOMICS;
HEALTH;
HUMAN;
INTERNATIONAL COOPERATION;
MOTIVATION;
NEGLECTED DISEASES;
ORGANIZATION AND MANAGEMENT;
SUPPLY AND DISTRIBUTION;
UNITED NATIONS;
WORLD HEALTH ORGANIZATION;
DEVELOPED COUNTRIES;
DEVELOPING COUNTRIES;
DRUG COSTS;
DRUG INDUSTRY;
GLOBAL HEALTH;
GOALS;
HUMANS;
INTELLECTUAL PROPERTY;
INTERNATIONAL AGENCIES;
INTERNATIONAL COOPERATION;
NEGLECTED DISEASES;
PHARMACEUTICAL PREPARATIONS;
PRIVATIZATION;
RESEARCH SUPPORT AS TOPIC;
UNITED NATIONS;
WORLD HEALTH ORGANIZATION;
|
EID: 85014686436
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2016.17994 Document Type: Note |
Times cited : (6)
|
References (8)
|